| http://www.w3.org/ns/prov#value | - We believe Johnson Matthey's expertise and proven track record in the manufacture of controlled drug substances are a natural fit with our unique approach to improving drugs with high abuse potential that is based on creating inherently abuse resistant molecules through chemical modification, commented Travis Mickle, Ph.D., President and Chief Scientific Officer of KemPharm.
|
